278 results on '"Gatzemeier, Ulrich"'
Search Results
2. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
3. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
4. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial
5. Characteristics, treatment patterns and outcomes of patients with small cell lung cancer—A retrospective single institution analysis
6. Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non–Small-Cell Lung Cancer: A Case-Based Review
7. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
8. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study
9. Lung Toxicity of Chemotherapeutic Agents
10. Lactate dehydrogenase as prognostic factor in limited and extensive disease stage small cell lung cancer – A retrospective single institution analysis
11. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study
12. XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
13. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
14. Nichtkleinzelliges Lungenkarzinom – Diagnostik und stadienadaptierte Therapie
15. Oral Vinorelbine in the Treatment of Non-Small Cell Lung Cancer: Rationale and Implications for Patient Management
16. Neue molekulare Therapien beim nichtkleinzelligen Lungenkarzinom am Beispiel der EGFR/HER1-Inhibition
17. A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies
18. Gefitinib Monotherapy in Chemotherapy-Naive Patients with Inoperable Stage III/IV Non-Small-Cell Lung Cancer
19. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: Quality of life and 6-years’-follow-up results from a randomised phase III trial
20. Efficacy and safety of bronchoscopic laser therapy in patients with tracheal and bronchial obstruction: a retrospective single institution report
21. Vorwort
22. Thalidomide in lung cancer therapy—what have we learned?
23. Incidence of Febrile Neutropenia and Myelotoxicity of Chemotherapy: A Meta-Analysis of Biosimilar G-CSF Studies in Breast Cancer, Lung Cancer, and Non-Hodgkinʼs Lymphoma
24. Vorwort
25. A Pilot Trial of Gefitinib in Combination with Docetaxel in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
26. Gefitinib (‘Iressa’): a new therapy for advanced non-small-cell lung cancer
27. Benefit in lung function improvement and side-effect profile of long-term responders: An analysis of 14 NSCLC patients treated for at least 9 months with gefitinib
28. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen
29. Vorwort
30. Diagnostics and staging procedures in non-small cell lung cancer – is less more?
31. Tumortherapie im Spannungsfeld von Pharmakoökonomie und Innovation*
32. Vorwort
33. «Pillnitzer Interdisziplinäres Gespräch 2007» - Zusammenfassung
34. «Pillnitzer interdisziplinäres Gespräch» - Zusammenfassung
35. Vorwort
36. EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Report of a 3-Year Compassionate Use Experience with Gefitinib in Stage IIIB/IV Outpatients
37. Randomized Multicenter Phase II Study of Gemcitabine Versus Docetaxel as First-Line Therapy with Second-Line Crossover in Advanced-Stage Non-Small-Cell Lung Cancer
38. Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: National Cancer Institute of Canada–Clinical Trials Group Study BR.18
39. Pemetrexed–cisplatin combination in mesothelioma
40. Phase III Study of Matrix Metalloproteinase Inhibitor Prinomastat in Non–Small-Cell Lung Cancer
41. Chemotherapy in stage-IV NSCLC
42. Formation of benzo[a]pyrene-DNA adducts in blood monocytes from lung cancer patients with a familial history of lung cancer
43. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
44. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
45. Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer
46. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
47. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma
48. Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer
49. An open label, pilot trial of two doses of ZD1839 in combination with docetaxel in patients with advanced or metastatic non-small-cell lung cancer (NSCLC): Preliminary safety results
50. Relationship between concentrations of trastuzumab and shed HER2 extracellular domain (ECD): A meta-analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.